Conatus Pharmaceuticals (CNAT) Stock Price, News & Analysis

Company Overview

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company is also developing CTS-2090, an orally active inhibitor of caspase 1, which is in preclinical development stage for treating chronic diseases involving inflammasome pathways. The company has a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $0.03 to $0.03
• 50-Day Range: $0.56 to $1.34
• 52-Week Range: $0.23 to $1.07
• Volume: 5 shs
• Average Volume: 1.28 million shs
• Market Capitalization: $895,590.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CNAT Stock Analysis - Frequently Asked Questions

How were Conatus Pharmaceuticals' earnings last quarter?

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) posted its quarterly earnings data on Friday, May, 1st. The biotechnology company reported ($0.10) EPS for the quarter, hitting analysts' consensus estimates of ($0.10). Conatus Pharmaceuticals had a negative net margin of 52.42% and a negative trailing twelve-month return on equity of 48.22%.

What other stocks do shareholders of Conatus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Conatus Pharmaceuticals investors own include KNOT Offshore Partners (KNOP), Trevena (TRVN), PPL (PPL), (CASC) (CASC), Vaxart (VXRT), Antares Pharma (ATRS) and Dextera Surgical (DXTR).

Company Calendar

• Last Earnings: 5/01/2020
• Today: 2/22/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CNAT
• CUSIP: N/A
• CIK: 1383701
• Web: www.conatuspharma.com
• Phone: 858-376-2600
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-11,390,000.00
• Net Margins: -52.42%
• Pretax Margin: N/A
• Return on Equity: -48.22%
• Return on Assets: -39.32%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 16.28
• Quick Ratio: 16.28

Sales & Book Value

• Annual Sales: $21.72 million
• Price / Sales: 0.04
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.53 per share
• Price / Book: 0.05

Miscellaneous

• Outstanding Shares: 33,170,000
• Free Float: N/A
• Market Cap: $895,590.00
• Optionable: Not Optionable
• Beta: 1.84